| 000 | 01738 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515021540.0 | ||
| 264 | 0 | _c20060622 | |
| 008 | 200606s 0 0 eng d | ||
| 022 | _a1743-4297 | ||
| 024 | 7 |
_a10.1038/ncpcardio0512 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNeumann, Franz-Josef | |
| 245 | 0 | 0 |
_aDoes abciximab provide long-term benefit for patients with acute myocardial infarction treated with stents? _h[electronic resource] |
| 260 |
_bNature clinical practice. Cardiovascular medicine _cApr 2006 |
||
| 300 |
_a190-1 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAngioplasty, Balloon, Coronary _xmethods |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aConfidence Intervals |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aElectrocardiography |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadministration & dosage |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdiagnosis |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aReference Values |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aStents |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tNature clinical practice. Cardiovascular medicine _gvol. 3 _gno. 4 _gp. 190-1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ncpcardio0512 _zAvailable from publisher's website |
| 999 |
_c16175396 _d16175396 |
||